NAGE · Niagen Bioscience, Inc. · Metrics
Market Cap
$242.01M
Shares
79.13M
NAGE metrics
70 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$3.05
Market cap
$242.01M
Price action
20 metricsPrice change (1W)
-1.0%
Price change (30D)
+1.6%
Price change (3M)
-11.7%
Price change (6M)
-40.6%
Price change (YTD)
-51.3%
Price change (1Y)
-67.2%
Trailing year
Price change (5Y)
-59.9%
52-week high
$10.24
52-week low
$2.96
Change from 52-week high
-69.7%
Change from 52-week low
+4.7%
Annualized volatility
50.4%
Annualized volatility (3M)
52.1%
Beta
1.3
RSI (14D)
44.8
Price vs SMA 50
-4.7%
Price vs SMA 200
-33.2%
Avg volume (3M)
649,465
Relative volume
0.8
Average dollar volume
$2.15M
Company
3 metricsSector
Consumer Defensive
Industry
Packaged Foods
Shares outstanding
79.13M
Valuation
12 metricsP / E (TTM)
17.2
Trailing earnings · reciprocal yield 5.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 53.3%
P / book
2.9
reciprocal yield 34.1%
FCF yield
—
TTM · current market cap
Buyback yield
2.2%
P / FCF
—
P / operating cash flow
40.7
reciprocal yield 2.5%
Earnings yield
6.6%
Historical valuation
8 metricsP / E historical average (3Y)
73.1×
reciprocal yield 1.4%
P / E historical average (5Y)
73.1×
reciprocal yield 1.4%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-04
Profitability
9 metricsGross margin
64.2%
Operating margin
8.2%
Trailing 12 months
Net margin
12.4%
Gross profit (TTM)
$82.92M
Operating profit (TTM)
$10.60M
Net income (TTM)
$15.99M
Trailing 12 months
Diluted EPS (TTM)
$0.18
FCF margin
—
Effective tax rate
6.1%
Growth
11 metricsRevenue growth YoY
-4.3%
Year over year
Net income growth YoY
-73.3%
Revenue (TTM)
$129.08M
Trailing 12 months
EPS growth YoY
-75.0%
Shares change YoY
-4.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+21.6%
Revenue CAGR (5Y)
+16.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
19.4%
Return on assets
15.0%
Debt / equity
—
Current ratio
6.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$66.74M
Total assets
$106.59M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
$5.95M
Capital expenditures (TTM)
$427,000
R&D (TTM)
$6.50M
SG&A (TTM)
—
Stock compensation (TTM)
$6.94M
R&D / revenue
5.0%
Stock compensation / revenue
5.4%
Ownership (13F)
3 metrics13F filers
140
13F filer change QoQ
-6
Institutional ownership
40.6%
Short interest
3 metricsShort interest
5.5%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
54 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1386570
CUSIP
171077407
13F (30d)
88 filings
88 filers
Visit website
Investor relations